ArticleProbiotics and antimicrobial proteins2023
Lactobacillus johnsonii BFE6154 Ameliorates Diet-Induced Hypercholesterolemia.
Article in Probiotics and antimicrobial proteins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Development of a gene-editing strategy to overcome genetic intractability inJournal of bacteriology · 2026Article
- Lactobacillus johnsonii DM2420 Alleviates Dyslipidemia, Remodels Gut Microbiota, and Modulates the Intestinal CD36/SREBP1 Signaling Axis.Probiotics and antimicrobial proteins · 2026Article
- Paocai-derived Lactiplantibacillus plantarum NMG11 can maintain lipid metabolic homeostasis, alleviate inflammation, and remodel the gut microbiota in high-cholesterol diet-fed mice.Probiotics and antimicrobial proteins · 2026Article
- Sleeve gastrectomy protects lean mice from future obesity.bioRxiv : the preprint server for biology · 2026Article
- Lactobacillus johnsonii-derived extracellular vesicles carrying GAPDH protect against ulcerative colitis through modulating macrophage polarization.Journal of advanced research · 2026Article
- From Probiotics to Postbiotics-An Update on Their Biotherapeutic Potential and the Emerging Strategies in Human Health.International journal of molecular sciences · 2026Review
- Strain-resolved biology ofFrontiers in veterinary science · 2026Review
- Unveiling the potential ofFrontiers in microbiology · 2025Review
- Article
- Article
- Cholesterol-Lowering Effect of Polysaccharides fromFoods (Basel, Switzerland) · 2024Article
- Article
- Genome Analysis for Cholesterol-Lowing Action and Bacteriocin Production ofMicroorganisms · 2024Article
- Research advances in the therapy of metabolic syndrome.Frontiers in pharmacology · 2024Review
- Genomic analysis and functional properties ofFrontiers in microbiology · 2024Article
- The Effects ofMicroorganisms · 2023Review
- Article
- Article
- Effects of the Probiotic Lactiplantibacillus plantarum KU15120 Derived from Korean Homemade Diced-Radish Kimchi Against Oxidation and Adipogenesis.Probiotics and antimicrobial proteins · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The functional characteristics of Lactobacillus johnsonii BFE6154, first isolated from Maasai traditional fermented milk, were previously identified in vitro, but its cholesterol-lowering properties have not been verified yet. In this study, we investigated the effect of L. johnsonii BFE6154 on cholesterol regulation and the mode of action. Stimulation of Caco-2 intestinal epithelial cells with L. johnsonii BFE6154 downregulated the gene expression of Niemann-Pick C1-like 1 (NPC1L1) through the activation of liver X receptor (LXR). Also, stimulation of HepG2 cells with the metabolites produced by L. johnsonii BFE6154 revealed an increase in the gene expression of low-density lipoprotein receptor (LDLR). Oral administration of L. johnsonii BFE6154 in mice receiving a high-fat and high-cholesterol diet (HFHCD), reduced total cholesterol and low-density lipoprotein-cholesterol (LDL) and increased high-density lipoprotein-cholesterol (HDL) in the blood, compared to the control. Diet-induced hypercholesterolemic mice receiving L. johnsonii BFE6154 showed a suppression of cholesterol absorption under the control of NPC1L1 in the intestine. Furthermore, L. johnsonii BFE6154 consumption ameliorated the hepatic cholesterol level and LDLR expression, which was reduced by HFHCD. These molecular modulations led to the increase of cholesterol excretion and the decrease of cholesterol levels in the feces and liver, respectively. Taken together, these results suggest that L. johnsonii BFE6154 may protect against diet-induced hypercholesterolemia through the regulation of cholesterol metabolism in the intestine and liver.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.